26586-27-6 Usage
Uses
Used in Pharmaceutical Synthesis:
3-AMINO-4-PIPERIDIN-1-YL-BENZOIC ACID is used as a key intermediate in the synthesis of various pharmaceutical compounds, leveraging its structural features to create drugs with targeted therapeutic effects.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-AMINO-4-PIPERIDIN-1-YL-BENZOIC ACID is utilized as a structural component in the design and development of new drugs, contributing to the advancement of treatments for a range of diseases.
Used in Drug Discovery:
3-AMINO-4-PIPERIDIN-1-YL-BENZOIC ACID plays a significant role in drug discovery, where its potential therapeutic applications are explored and harnessed to create innovative pharmaceutical agents.
Used in Development of Novel Treatments:
3-AMINO-4-PIPERIDIN-1-YL-BENZOIC ACID is employed in the research and development of novel treatment options for various medical conditions, capitalizing on its capacity to interact with specific biological targets and cellular mechanisms.
Check Digit Verification of cas no
The CAS Registry Mumber 26586-27-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,6,5,8 and 6 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 26586-27:
(7*2)+(6*6)+(5*5)+(4*8)+(3*6)+(2*2)+(1*7)=136
136 % 10 = 6
So 26586-27-6 is a valid CAS Registry Number.
InChI:InChI=1/C12H16N2O2/c13-10-8-9(12(15)16)4-5-11(10)14-6-2-1-3-7-14/h4-5,8H,1-3,6-7,13H2,(H,15,16)/p-1
26586-27-6Relevant articles and documents
Potent 2′-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents
Patch, Raymond J.,Brandt, Benjamin M.,Asgari, Davoud,Baindur, Nand,Chadha, Naresh K.,Georgiadis, Taxiarchis,Cheung, Wing S.,Petrounia, Ioanna P.,Donatelli, Robert R.,Chaikin, Margery A.,Player, Mark R.
, p. 6070 - 6074 (2008/03/18)
A series of 2′-aminoanilides have been identified which exhibit potent and selective inhibitory activity against the cFMS tyrosine kinase. Initial SAR studies within this series are described which examine aroyl and amino group substitutions, as well as the introduction of hydrophilic substituents on the benzene core. Compound 47 inhibits the isolated enzyme (IC50 = 0.027 μM) and blocks CSF-1-induced proliferation of bone marrow-derived macrophages (IC50 = 0.11 μM) and as such, serves as a lead candidate for further optimization studies.
